Leadership

Kim serves as CENTOGENE’s Chief Executive Officer. She has more than 30 years’ global commercial expertise in the biopharmaceutical space, with significant experience across multiple geographies, including Europe, the U.S., APAC, and LATAM. Most recently, Kim served as CEO of Orphazyme, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases. Prior to this role, she worked at Shire Pharmaceuticals, where she served as Head of International Commercial for Shire’s Specialty and Rare Disease portfolio. Before Shire, Kim spent nearly 15 years at Novartis in a number of senior management roles, including Global Head Corporate Public Affairs, Global Business Franchise Head, and Country Management. Kim is on the Board of Recordati S.p.A and Novozymes A/S.

Ian is a globally experienced industry leader with over 25 years of experience in the pharmaceutical and life sciences sector. He has worked with leading organizations across the globe including IQVIA, Clinerion, AETION, VARA AI, and TriNetX – developing a comprehensive understanding of clinical development and real-world evidence generation.

With a strong background in business administration, human resources, finance, and legal affairs, Ian has led global teams, exceeded significant growth targets, and conducted operations in over 20 countries worldwide. Having held executive and board positions throughout Europe, Ian has demonstrated his ability to form strategic partnerships, lead global data collaborations, and support the growth of emerging biotech and pharmaceutical companies.

Prof. Peter Bauer, M.D., serves as CENTOGENE's Chief Medical and Genomic Officer, where he combines an extensive clinical and medical understanding of genetic testing with an excellent knowledge of the latest scientific developments.

Peter is passionate about turning medical questions into complete and fast analytical processes – ensuring that medically-driven results are brought to clinicians and patients immediately.

He received his board certification in Human Genetics in 2006 and previously headed the Molecular Diagnostic Laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Peter has authored more than 250 publications in Neurogenetics, Oncogenetics, Cardiogenetics, and Sequencing Technology.